APO Research
Talk to an analyst

APO RESEARCH · REPORT

Live Biotherapeutic Products (LBP) and Microbiome CDMO Service

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Analysis and Forecast 2026-2032

5 June 2026259 pages

Choose your research edition.

Industry ResearchLive Biotherapeutic Products (LBP) and Microbiome CDMO Service Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Analysis and Forecast 2026-2032259 pages · $4,950 USD

Market perspective

The global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Live Biotherapeutic Products (LBP) and Microbiome CDMO Service is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Live Biotherapeutic Products (LBP) and Microbiome CDMO Service is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Live Biotherapeutic Products (LBP) and Microbiome CDMO Service is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Live Biotherapeutic Products (LBP) and Microbiome CDMO Service is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Live Biotherapeutic Products (LBP) and Microbiome CDMO Service include Lallemand Health Solutions, Wacker Chemie AG, Biose Industrie, List Biological Labs, Inc., NIZO, SGS (Quay Pharmaceuticals), Assembly Biosciences, Inc., Recipharm (Arranta Bio) and Bacthera (Novonesis+Lonza), etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Live Biotherapeutic Products (LBP) and Microbiome CDMO Service, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Live Biotherapeutic Products (LBP) and Microbiome CDMO Service, also provides the revenue of main regions and countries. Of the upcoming market potential for Live Biotherapeutic Products (LBP) and Microbiome CDMO Service, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Live Biotherapeutic Products (LBP) and Microbiome CDMO Service revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Live Biotherapeutic Products (LBP) and Microbiome CDMO Service revenue, projected growth trends, production technology, application and end-user industry.

Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Segment by Company

Lallemand Health Solutions

Wacker Chemie AG

Biose Industrie

List Biological Labs, Inc.

NIZO

SGS (Quay Pharmaceuticals)

Assembly Biosciences, Inc.

Recipharm (Arranta Bio)

Bacthera (Novonesis+Lonza)

Smaltis

Lonza

vermicon AG

Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Segment by Type

Solid Dosage Form

Liquid Dosage Form

Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Segment by Application

Digestive System Diseases

Immune System Diseases

Metabolic Diseases

Other

Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Live Biotherapeutic Products (LBP) and Microbiome CDMO Service and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Live Biotherapeutic Products (LBP) and Microbiome CDMO Service.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Live Biotherapeutic Products (LBP) and Microbiome CDMO Service in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Live Biotherapeutic Products (LBP) and Microbiome CDMO Service company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Live Biotherapeutic Products (LBP) and Microbiome CDMO Service revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Solid Dosage Form Major Player Table 3. Liquid Dosage Form Major Player Table 4. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Digestive System Diseases Major Player Table 6. Immune System Diseases Major Player Table 7. Metabolic Diseases Major Player Table 8. Other Major Player Table 9. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Industry Trends Table 10. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Industry Drivers Table 11. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Industry Opportunities and Challenges Table 12. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Industry Restraints Table 13. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Share by Region (2021-2026) Table 16. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Share by Region (2027-2032) Table 18. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Players (US$ Million) & (2021-2026) Table 19. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue Market Share by Players (2021-2026) Table 20. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Key Players Ranking, 2024 VS 2025 VS 2026 Table 21. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Key Players Headquarters & Area Served Table 22. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Players, Product Type & Application Table 23. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Players Establishment Date Table 24. Global Players Market Concentration Ratio (CR5 and HHI) Table 25. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 26. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Type (2021-2026) & (US$ Million) Table 28. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Type (2027-2032) & (US$ Million) Table 29. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue Market Share by Type (2021-2026) Table 30. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue Market Share by Type (2027-2032) Table 31. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Application (2021-2026) & (US$ Million) Table 33. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Application (2027-2032) & (US$ Million) Table 34. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue Market Share by Application (2021-2026) Table 35. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue Market Share by Application (2027-2032) Table 36. Lallemand Health Solutions Company Information Table 37. Lallemand Health Solutions Business Overview Table 38. Lallemand Health Solutions Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Lallemand Health Solutions Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product Portfolio Table 40. Lallemand Health Solutions Recent Development Table 41. Wacker Chemie AG Company Information Table 42. Wacker Chemie AG Business Overview Table 43. Wacker Chemie AG Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Wacker Chemie AG Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product Portfolio Table 45. Wacker Chemie AG Recent Development Table 46. Biose Industrie Company Information Table 47. Biose Industrie Business Overview Table 48. Biose Industrie Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Biose Industrie Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product Portfolio Table 50. Biose Industrie Recent Development Table 51. List Biological Labs, Inc. Company Information Table 52. List Biological Labs, Inc. Business Overview Table 53. List Biological Labs, Inc. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. List Biological Labs, Inc. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product Portfolio Table 55. List Biological Labs, Inc. Recent Development Table 56. NIZO Company Information Table 57. NIZO Business Overview Table 58. NIZO Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. NIZO Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product Portfolio Table 60. NIZO Recent Development Table 61. SGS (Quay Pharmaceuticals) Company Information Table 62. SGS (Quay Pharmaceuticals) Business Overview Table 63. SGS (Quay Pharmaceuticals) Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. SGS (Quay Pharmaceuticals) Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product Portfolio Table 65. SGS (Quay Pharmaceuticals) Recent Development Table 66. Assembly Biosciences, Inc. Company Information Table 67. Assembly Biosciences, Inc. Business Overview Table 68. Assembly Biosciences, Inc. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. Assembly Biosciences, Inc. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product Portfolio Table 70. Assembly Biosciences, Inc. Recent Development Table 71. Recipharm (Arranta Bio) Company Information Table 72. Recipharm (Arranta Bio) Business Overview Table 73. Recipharm (Arranta Bio) Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. Recipharm (Arranta Bio) Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product Portfolio Table 75. Recipharm (Arranta Bio) Recent Development Table 76. Bacthera (Novonesis+Lonza) Company Information Table 77. Bacthera (Novonesis+Lonza) Business Overview Table 78. Bacthera (Novonesis+Lonza) Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. Bacthera (Novonesis+Lonza) Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product Portfolio Table 80. Bacthera (Novonesis+Lonza) Recent Development Table 81. Smaltis Company Information Table 82. Smaltis Business Overview Table 83. Smaltis Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. Smaltis Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product Portfolio Table 85. Smaltis Recent Development Table 86. Lonza Company Information Table 87. Lonza Business Overview Table 88. Lonza Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 89. Lonza Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product Portfolio Table 90. Lonza Recent Development Table 91. vermicon AG Company Information Table 92. vermicon AG Business Overview Table 93. vermicon AG Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 94. vermicon AG Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product Portfolio Table 95. vermicon AG Recent Development Table 96. North America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Type (2021-2026) & (US$ Million) Table 97. North America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Type (2027-2032) & (US$ Million) Table 98. North America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Application (2021-2026) & (US$ Million) Table 99. North America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Application (2027-2032) & (US$ Million) Table 100. North America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 101. North America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Country (2021-2026) & (US$ Million) Table 102. North America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Country (US$ Million) & (2027-2032) Table 103. Europe Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Type (2021-2026) & (US$ Million) Table 104. Europe Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Type (2027-2032) & (US$ Million) Table 105. Europe Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Application (2021-2026) & (US$ Million) Table 106. Europe Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Application (2027-2032) & (US$ Million) Table 107. Europe Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 108. Europe Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Country (2021-2026) & (US$ Million) Table 109. Europe Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Country (US$ Million) & (2027-2032) Table 110. China Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Type (2021-2026) & (US$ Million) Table 111. China Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Type (2027-2032) & (US$ Million) Table 112. China Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Application (2021-2026) & (US$ Million) Table 113. China Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Application (2027-2032) & (US$ Million) Table 114. Asia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Type (2021-2026) & (US$ Million) Table 115. Asia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Type (2027-2032) & (US$ Million) Table 116. Asia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Application (2021-2026) & (US$ Million) Table 117. Asia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Application (2027-2032) & (US$ Million) Table 118. Asia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 119. Asia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Region (US$ Million) & (2021-2026) Table 120. Asia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Region (US$ Million) & (2027-2032) Table 121. SAMEA Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Type (2021-2026) & (US$ Million) Table 122. SAMEA Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Type (2027-2032) & (US$ Million) Table 123. SAMEA Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Application (2021-2026) & (US$ Million) Table 124. SAMEA Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Application (2027-2032) & (US$ Million) Table 125. SAMEA Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 126. SAMEA Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Country (2021-2026) & (US$ Million) Table 127. SAMEA Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Country (US$ Million) & (2027-2032) Table 128. Research Programs/Design for This Report Table 129. Authors List of This Report Table 130. Secondary Sources Table 131. Primary Sources List of Figures Figure 1. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Image Figure 2. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size Share 2021 VS 2025 VS 2032 Figure 4. Solid Dosage Form Image Figure 5. Liquid Dosage Form Image Figure 6. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size Share 2021 VS 2025 VS 2032 Figure 8. Digestive System Diseases Image Figure 9. Immune System Diseases Image Figure 10. Metabolic Diseases Image Figure 11. Other Image Figure 12. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size (US$ Million) & (2021-2032) Figure 13. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Share by Region: 2021 VS 2025 VS 2032 Figure 15. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Players Revenue Share Top 10 and Top 5 in 2025 Figure 16. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue Market Share by Type (2021-2032) Figure 20. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 22. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue Market Share by Application (2021-2032) Figure 23. North America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue YoY Growth (2021-2032) & (US$ Million) Figure 24. North America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue Share by Type (2021-2032) Figure 25. North America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue Share by Application (2021-2032) Figure 26. North America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue Share by Country (2021-2032) Figure 27. United States Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Canada Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Mexico Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Europe Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue YoY Growth (2021-2032) & (US$ Million) Figure 31. Europe Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue Share by Type (2021-2032) Figure 32. Europe Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue Share by Application (2021-2032) Figure 33. Europe Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue Share by Country (2021-2032) Figure 34. Germany Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. France Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. U.K. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Italy Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Spain Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Russia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Netherlands Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Nordic Countries Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. China Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue YoY Growth (2021-2032) & (US$ Million) Figure 43. China Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue Share by Type (2021-2032) Figure 44. China Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue Share by Application (2021-2032) Figure 45. Asia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. Asia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue Share by Type (2021-2032) Figure 47. Asia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue Share by Application (2021-2032) Figure 48. Asia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue Share by Region (2021-2032) Figure 49. Japan Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. South Korea Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. India Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Australia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Taiwan Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Southeast Asia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. SAMEA Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue YoY Growth (2021-2032) & (US$ Million) Figure 56. SAMEA Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue Share by Type (2021-2032) Figure 57. SAMEA Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue Share by Application (2021-2032) Figure 58. SAMEA Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue Share by Country (2021-2032) Figure 59. Brazil Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Argentina Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Chile Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Colombia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Peru Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Saudi Arabia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Israel Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. UAE Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Turkey Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Iran Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Egypt Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Solid Dosage Form
  • Liquid Dosage Form
Applications
  • Digestive System Diseases
  • Immune System Diseases
  • Metabolic Diseases
  • Other
Companies covered
  • Lallemand Health Solutions
  • Wacker Chemie AG
  • Biose Industrie
  • List Biological Labs, Inc.
  • NIZO
  • SGS (Quay Pharmaceuticals)
  • Assembly Biosciences, Inc.
  • Recipharm (Arranta Bio)
  • Bacthera (Novonesis+Lonza)
  • Smaltis
  • Lonza
  • vermicon AG

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market by Type
  3. 1.2.1 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Solid Dosage Form
  5. 1.2.3 Liquid Dosage Form
  6. 1.3 Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market by Application
  7. 1.3.1 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Digestive System Diseases
  9. 1.3.3 Immune System Diseases
  10. 1.3.4 Metabolic Diseases
  11. 1.3.5 Other
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Dynamics
  1. 2.1 Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Industry Trends
  2. 2.2 Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Industry Drivers
  3. 2.3 Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Industry Opportunities and Challenges
  4. 2.4 Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Perspective (2021-2032)
  2. 3.2 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Growth Trends by Region
  3. 3.2.1 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Region (2021-2026)
  5. 3.2.3 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Players
  2. 4.1.1 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Players (2021-2026)
  3. 4.1.2 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Key Players Headquarters & Area Served
  7. 4.4 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Players, Product Type & Application
  8. 4.5 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market CR5 and HHI
  11. 4.6.3 2025 Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Tier 1, Tier 2, and Tier 3
5 Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Type
  1. 5.1 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Type (2021-2032)
  3. 5.3 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue Market Share by Type (2021-2032)
6 Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Application
  1. 6.1 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Application (2021-2032)
  3. 6.3 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Lallemand Health Solutions
  2. 7.1.1 Lallemand Health Solutions Company Information
  3. 7.1.2 Lallemand Health Solutions Business Overview
  4. 7.1.3 Lallemand Health Solutions Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Lallemand Health Solutions Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product Portfolio
  6. 7.1.5 Lallemand Health Solutions Recent Developments
  7. 7.2 Wacker Chemie AG
  8. 7.2.1 Wacker Chemie AG Company Information
  9. 7.2.2 Wacker Chemie AG Business Overview
  10. 7.2.3 Wacker Chemie AG Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Wacker Chemie AG Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product Portfolio
  12. 7.2.5 Wacker Chemie AG Recent Developments
  13. 7.3 Biose Industrie
  14. 7.3.1 Biose Industrie Company Information
  15. 7.3.2 Biose Industrie Business Overview
  16. 7.3.3 Biose Industrie Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Biose Industrie Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product Portfolio
  18. 7.3.5 Biose Industrie Recent Developments
  19. 7.4 List Biological Labs, Inc.
  20. 7.4.1 List Biological Labs, Inc. Company Information
  21. 7.4.2 List Biological Labs, Inc. Business Overview
  22. 7.4.3 List Biological Labs, Inc. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue and Gross Margin (2021-2026)
  23. 7.4.4 List Biological Labs, Inc. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product Portfolio
  24. 7.4.5 List Biological Labs, Inc. Recent Developments
  25. 7.5 NIZO
  26. 7.5.1 NIZO Company Information
  27. 7.5.2 NIZO Business Overview
  28. 7.5.3 NIZO Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue and Gross Margin (2021-2026)
  29. 7.5.4 NIZO Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product Portfolio
  30. 7.5.5 NIZO Recent Developments
  31. 7.6 SGS (Quay Pharmaceuticals)
  32. 7.6.1 SGS (Quay Pharmaceuticals) Company Information
  33. 7.6.2 SGS (Quay Pharmaceuticals) Business Overview
  34. 7.6.3 SGS (Quay Pharmaceuticals) Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue and Gross Margin (2021-2026)
  35. 7.6.4 SGS (Quay Pharmaceuticals) Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product Portfolio
  36. 7.6.5 SGS (Quay Pharmaceuticals) Recent Developments
  37. 7.7 Assembly Biosciences, Inc.
  38. 7.7.1 Assembly Biosciences, Inc. Company Information
  39. 7.7.2 Assembly Biosciences, Inc. Business Overview
  40. 7.7.3 Assembly Biosciences, Inc. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Assembly Biosciences, Inc. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product Portfolio
  42. 7.7.5 Assembly Biosciences, Inc. Recent Developments
  43. 7.8 Recipharm (Arranta Bio)
  44. 7.8.1 Recipharm (Arranta Bio) Company Information
  45. 7.8.2 Recipharm (Arranta Bio) Business Overview
  46. 7.8.3 Recipharm (Arranta Bio) Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Recipharm (Arranta Bio) Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product Portfolio
  48. 7.8.5 Recipharm (Arranta Bio) Recent Developments
  49. 7.9 Bacthera (Novonesis+Lonza)
  50. 7.9.1 Bacthera (Novonesis+Lonza) Company Information
  51. 7.9.2 Bacthera (Novonesis+Lonza) Business Overview
  52. 7.9.3 Bacthera (Novonesis+Lonza) Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Bacthera (Novonesis+Lonza) Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product Portfolio
  54. 7.9.5 Bacthera (Novonesis+Lonza) Recent Developments
  55. 7.10 Smaltis
  56. 7.10.1 Smaltis Company Information
  57. 7.10.2 Smaltis Business Overview
  58. 7.10.3 Smaltis Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Smaltis Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product Portfolio
  60. 7.10.5 Smaltis Recent Developments
  61. 7.11 Lonza
  62. 7.11.1 Lonza Company Information
  63. 7.11.2 Lonza Business Overview
  64. 7.11.3 Lonza Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Lonza Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product Portfolio
  66. 7.11.5 Lonza Recent Developments
  67. 7.12 vermicon AG
  68. 7.12.1 vermicon AG Company Information
  69. 7.12.2 vermicon AG Business Overview
  70. 7.12.3 vermicon AG Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue and Gross Margin (2021-2026)
  71. 7.12.4 vermicon AG Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product Portfolio
  72. 7.12.5 vermicon AG Recent Developments
8 North America
  1. 8.1 North America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue (2021-2032)
  2. 8.2 North America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Type (2021-2032)
  3. 8.2.1 North America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Type (2021-2026)
  4. 8.2.2 North America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Type (2027-2032)
  5. 8.3 North America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue Share by Type (2021-2032)
  6. 8.4 North America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Application (2021-2032)
  7. 8.4.1 North America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Application (2021-2026)
  8. 8.4.2 North America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Application (2027-2032)
  9. 8.5 North America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue Share by Application (2021-2032)
  10. 8.6 North America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Country
  11. 8.6.1 North America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Country (2021-2026)
  13. 8.6.3 North America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue (2021-2032)
  2. 9.2 Europe Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Type (2021-2032)
  3. 9.2.1 Europe Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Type (2021-2026)
  4. 9.2.2 Europe Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Type (2027-2032)
  5. 9.3 Europe Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue Share by Type (2021-2032)
  6. 9.4 Europe Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Application (2021-2032)
  7. 9.4.1 Europe Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Application (2021-2026)
  8. 9.4.2 Europe Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Application (2027-2032)
  9. 9.5 Europe Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue Share by Application (2021-2032)
  10. 9.6 Europe Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Country
  11. 9.6.1 Europe Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Country (2021-2026)
  13. 9.6.3 Europe Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue (2021-2032)
  2. 10.2 China Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Type (2021-2032)
  3. 10.2.1 China Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Type (2021-2026)
  4. 10.2.2 China Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Type (2027-2032)
  5. 10.3 China Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue Share by Type (2021-2032)
  6. 10.4 China Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Application (2021-2032)
  7. 10.4.1 China Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Application (2021-2026)
  8. 10.4.2 China Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Application (2027-2032)
  9. 10.5 China Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue (2021-2032)
  2. 11.2 Asia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Type (2021-2032)
  3. 11.2.1 Asia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Type (2021-2026)
  4. 11.2.2 Asia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Type (2027-2032)
  5. 11.3 Asia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue Share by Type (2021-2032)
  6. 11.4 Asia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Application (2021-2032)
  7. 11.4.1 Asia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Application (2021-2026)
  8. 11.4.2 Asia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Application (2027-2032)
  9. 11.5 Asia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue Share by Application (2021-2032)
  10. 11.6 Asia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Country
  11. 11.6.1 Asia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Country (2021-2026)
  13. 11.6.3 Asia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue (2021-2032)
  2. 12.2 SAMEA Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Type (2027-2032)
  5. 12.3 SAMEA Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Application (2027-2032)
  9. 12.5 SAMEA Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Country
  11. 12.6.1 SAMEA Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst